Oncology Focus (Prostate Cancer)

About Curium Pharma

Curium Pharma, founded in 2017 and headquartered in Paris, France, is a commercial-stage company and self-proclaimed global leader in nuclear medicine. It operates a fully integrated business model encompassing development, manufacturing, and global supply of a broad portfolio of over 50 diagnostic and therapeutic radiopharmaceuticals. With significant infrastructure including four manufacturing sites, 44 radiopharmacies, and a molybdenum processing plant, Curium serves over 6,000 customers in more than 60 countries. The company is executing a 2030 vision to solidify its position as an oncology-focused leader, expanding into key Asian markets and investing in new technologies, including artificial intelligence for image analysis.

Therapeutic Areas

Other Prostate Cancer Drugs